Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin
← Toate temele

Scleroză multiplă

Scleroza multiplă și viața cu aceasta.

71 de articole
← Toate secțiunile

Studii și știri

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuScleroză multiplăÎncredere înaltă23.06.2026

Residual cerebrospinal fluid inflammation persists during long-term natalizumab treatment in relapsing-remitting multiple sclerosis

This study measured 15 inflammatory biomarkers in cerebrospinal fluid from MS patients treated with natalizumab for varying durations, compared to untreated MS patients and healthy controls. While natalizumab significantly reduced most inflammatory markers, certain biomarkers including B cell maturation antigens and IL-10 remained elevated even after more than five years of treatment, suggesting incomplete suppression of intrathecal inflammation.

StudiuScleroză multiplăÎncredere înaltă23.06.2026

Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial

A 12-month randomized controlled trial evaluated dulaglutide (a GLP-1 receptor agonist) as adjunctive therapy alongside natalizumab in 28 patients with relapsing-remitting MS, measuring neurofilament light chain levels, brain MRI changes, and functional outcomes. Treatment with dulaglutide significantly reduced weight, BMI, and body fat while improving glucose tolerance and potentially showing neuroprotective effects.

StudiuScleroză multiplăÎncredere bună22.06.2026

Multiple Sclerosis in Morocco: Epidemiological, Clinical, and Therapeutic Profile

A descriptive study of 170 MS patients across Morocco found female predominance, relapsing-remitting MS as the most common type, and common symptoms including fatigue, cognitive issues, and spasticity. Disease-modifying therapies (interferon beta-1a, azathioprine) were used alongside traditional/complementary medicine (cupping, Quranic recitation, apitherapy), with professional activity, treatment satisfaction, and stress significantly associated with relapse frequency.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Neuroimaging Advances for Monitoring Multiple Sclerosis Worsening: GMSI-Supported Innovations

This review examines recent neuroimaging technologies including MRI, PET, ocular imaging, and machine learning supported by MS research initiatives to better detect early MS pathology and monitor treatment response. The authors emphasize that while these biomarkers show promise for predicting and monitoring disease progression and may serve as clinical trial endpoints, longitudinal studies are needed to translate these measures into routine clinical practice.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Cryptococcal Skin Infection in a Multiple Sclerosis Patient on Fingolimod: A Case Report

A 33-year-old woman with relapsing-remitting MS treated with fingolimod for 5 years developed a solitary skin lesion that proved to be cryptococcal infection on biopsy, likely due to severe lymphocyte suppression from the immunosuppressive therapy. The case highlights the importance of thorough investigation of persistent skin lesions in MS patients on fingolimod, as only 6 such cutaneous cryptococcal infections have been previously reported in the literature.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Alemtuzumab for Multiple Sclerosis: A Cochrane Systematic Review

This Cochrane review evaluates the efficacy and safety of alemtuzumab, a humanized monoclonal antibody, for treating various forms of multiple sclerosis compared to placebo or other active treatments. Primary outcomes include relapse-free survival, sustained disease progression, and adverse events, with secondary measures encompassing disability progression, quality of life, and MRI-detected lesions.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Biological aging in multiple sclerosis: mechanisms and therapeutic implications

This review examines how biological aging accelerates disease progression in multiple sclerosis, particularly in progressive forms resistant to current treatments. Evidence from animal models and clinical biomarkers (telomere length, DNA methylation) suggests MS patients experience accelerated aging, opening potential avenues for senotherapy-based interventions targeting aging-related pathways.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Reduced resting beat-to-beat blood pressure variability in females with relapsing-remitting multiple sclerosis

This study examined cardiovascular autonomic dysfunction in women with relapsing-remitting MS by measuring beat-to-beat blood pressure variability and sympathetic baroreflex sensitivity compared to healthy controls. The research hypothesized that reduced sympathetic control in MS patients leads to impaired blood pressure regulation, using continuous electrocardiogram and blood pressure monitoring along with muscle sympathetic nerve activity recordings.

StudiuScleroză multiplăÎncredere bună22.06.2026

The dual role of autophagy in multiple sclerosis: Protective and harmful mechanisms

This review examines autophagy—a cellular degradation process—as a double-edged sword in multiple sclerosis, showing both protective effects (reducing oxidative stress and inflammation) and harmful effects (promoting demyelination when over-activated). The paper discusses how autophagy modulates immune cell activation and oligodendrocyte function, suggesting selective autophagy modulation could be a therapeutic strategy depending on disease context.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Magnetic resonance fingerprinting in multiple sclerosis: T1 and T2 relaxation time analysis in tissue characterization

This cross-sectional study used magnetic resonance fingerprinting (MRF) to measure T1 and T2 relaxation times in brain tissue of healthy controls, relapsing-remitting MS patients, and secondary progressive MS patients, finding progressive increases in relaxation times across disease stages. The findings suggest MRF may be useful for quantitative tissue characterization and differentiation between MS disease subtypes and disease progression.

StudiuScleroză multiplăÎncredere bună22.06.2026

Neuropsychological Rehabilitation in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review

This systematic review examines scientific evidence on neuropsychological interventions targeting cognitive impairment in people with relapsing-remitting MS, a common disabling neurological disease in young adults. Analysis of 15 articles meeting rigorous inclusion criteria found that most cognitive rehabilitation programs demonstrated effectiveness, though methodological standardization remains lacking in this field.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Horizontal gene transfer in pathogenic bacteria shapes progressive multiple sclerosis

Research identifies a specific strain of Tyzzerella nexilis enriched in secondary progressive MS that carries numerous mobile genetic elements and lacks defence mechanisms against them. In germ-free mice, colonisation with this strain increases susceptibility to experimental autoimmune encephalomyelitis through TLR5 stimulation by flagella and production of neuroactive reduced sulphur compounds, suggesting horizontal gene transfer may drive MS progression via gut microbiome alterations.

StudiuScleroză multiplăÎncredere înaltă22.06.2026

Executive Functions in Relapsing-Remitting Multiple Sclerosis: A Comparative Study of Working Memory and Cognitive Control

This study compared executive function performance in 24 individuals with relapsing-remitting multiple sclerosis and 24 matched healthy controls using standardized cognitive tests. Results showed selective impairment in divided attention and working memory updating in MS patients under high cognitive demand, while attentional shifting and inhibition remained intact.

StudiuScleroză multiplăÎncredere bună21.06.2026

Depression and sedentary behaviour in women with multiple sclerosis

This cross-sectional study of 78 women (38 with relapsing-remitting MS and 40 healthy controls) examined the relationship between depressive symptoms and sedentary behavior in MS patients. The research found significant associations between depression and increased sedentary time in women with MS, suggesting depression is a key factor contributing to reduced physical activity in this population.